{"doi":"10.25251/x2k3y515","title":"Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study","abstract":"Introduction Amlitelimab, a fully human, nondepleting monoclonal antibody, binds OX40 ligand (OX40L) on antigen-presenting cells, preventing OX40L-OX40 interaction on activated T cells. In adults with moderate-to-severe atopic dermatitis (AD), amlitelimab demonstrated clinically meaningful improvements in AD lesions and pruritus, and reduced AD-related plasma and cutaneous biomarkers over 24 weeks compared with placebo-treated patients in Part 1 of STREAM-AD. This analysis evaluates the effect of amlitelimab on AD-related cytokines and chemokines, including those associated with Th2, Th1, and Th17/Th22 inflammation. Methods STREAM-AD (NCT05131477) was a 52-week, Phase 2b trial with two parts: a 24-week dose-ranging phase and a 28-week maintenance phase. In Part 1, adults with moderate-to-severe AD were randomized to receive subcutaneous amlitelimab (250mg with 500-mg loading dose, 250mg, 125mg, 62.5mg) or placebo every 4 weeks. Here, changes in inflammatory proteins from baseline to weeks 4 and 16 were evaluated utilizing an exploratory protein multiplex panel (Olink® Explore 384 Inflammation I, Olink Proteomics) on plasma from patients with AD treated with amlitelimab (n=300) vs placebo (n=76) in Part 1. Results Amlitelimab reduced plasma proteins associated with Th2 inflammation, including CCL13, CCL17, CCL22, CCL26, IL-13, and IL-24 (P<0.01 for all) from baseline to Week 16. It also reduced markers of Th1-related inflammation, including CXCL9, CXCL10, and TNF (P<0.01 for all), and Th17/22-related inflammation, including CCL20, IL-17A, IL-17C (P<0.01 for all), and IL-6 (P<0.05). Conclusion Amlitelimab significantly reduced proteins associated with AD inflammation in adults with moderate-to-severe AD, further supporting that OX40L blockade is a relevant target for treating AD-related inflammation.","journal":"SKIN The Journal of Cutaneous Medicine","year":2025,"id":580869,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9571,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":11471,"name":"Stephan Weidinger","orcid":"0000-0003-3944-252X","position":1,"is_corresponding":false},{"id":284872,"name":"Saeko Nakajima","orcid":"0000-0003-0831-1447","position":2,"is_corresponding":false},{"id":227789,"name":"Donald Y.M. Leung","orcid":"0000-0002-0177-3844","position":3,"is_corresponding":false},{"id":1491939,"name":"Charles Lynde","orcid":"0000-0001-9163-5463","position":4,"is_corresponding":false},{"id":487267,"name":"Karl Yen","orcid":"0009-0002-2337-2045","position":5,"is_corresponding":false},{"id":1492283,"name":"Jason Deng","orcid":null,"position":6,"is_corresponding":false},{"id":1005207,"name":"Shaima Belhechmi","orcid":"0000-0003-3505-7042","position":7,"is_corresponding":false},{"id":1492284,"name":"Natalie Rynkiewicz","orcid":null,"position":8,"is_corresponding":false},{"id":318991,"name":"Bob Geng","orcid":null,"position":0,"is_corresponding":true}],"reference_count":3,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:58:43.046112Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}